Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
!!Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Long-term follow-up after gene therapy for canavan disease
Paola Leone
, David Shera
, Scott W.J. McPhee
, Jeremy S. Francis
, Edwin H. Kolodny
, Larissa T. Bilaniuk
, Dah Jyuu Wang
, Mitra Assadi
, Olga Goldfarb
, H. Warren Goldman
, Andrew Freese
, Deborah Young
, Matthew J. During
, R. Jude Samulski
, Christopher G Janson
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
257
!!Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Long-term follow-up after gene therapy for canavan disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Gene Therapy
100%
Canavan Disease
100%
Aspartoacylase
100%
N-acetylaspartate
60%
AAV2
60%
Gene-gene
40%
Long-term Safety
20%
White Matter Damage
20%
Recombinant Adeno-associated Virus (rAAV)
20%
Clinical Assessment
20%
Prospective Cohort Study
20%
Seizure Frequency
20%
Clinical Status
20%
Efficacy Index
20%
Enzyme Activity
20%
Surrogate Marker
20%
Leukodystrophy
20%
Safety Data
20%
Infusion Site
20%
Generalized Linear Mixed Model
20%
Clinical Rating Scale
20%
Spongiform Degeneration
20%
Long-term Adverse Effects
20%
Psychomotor Development
20%
Brain Atrophy
20%
Severe Impairment
20%
Marker of Disease Progression
20%
Resonance Imaging
20%
AAV2 Vector
20%
Brain Infusion
20%
Vector Genomes
20%
Minimum 5-year Follow-up
20%
Intraparenchymal Delivery
20%
Progression Assessment
20%
Medicine and Dentistry
Gene Therapy
100%
Canavan Disease
100%
Aspartoacylase
100%
N Acetylaspartic Acid
60%
Disease Exacerbation
20%
Epileptic Seizure
20%
Clinical Assessment
20%
Infusion
20%
Adeno Associated Virus Vector
20%
Enzyme Activity
20%
Prospective Cohort Study
20%
Disease Marker
20%
Mixed Model
20%
Psychomotor Development
20%
Cerebral Atrophy
20%
Leukodystrophy
20%
Rating Scale
20%
Adverse Event
20%
Pharmacology, Toxicology and Pharmaceutical Science
Canavan Disease
100%
Aspartoacylase
100%
N Acetylaspartic Acid
60%
Prospective Cohort Study
20%
Mixed Model
20%
Disease Exacerbation
20%
Adverse Event
20%
Adeno Associated Virus Vector
20%
Disease Marker
20%
Brain Atrophy
20%
Enzymes
20%
Leukodystrophy
20%
Biochemistry, Genetics and Molecular Biology
Gene Therapy
100%
Aspartoacylase
100%
Canavan Disease
100%
Aspartic Acid
60%
Prospective Cohort Study
20%
Enzyme Activity
20%
Adeno Associated Virus Vector
20%
Psychomotor Development
20%
Neuroscience
Aspartoacylase
100%
Canavan Disease
100%
N-Acetylaspartic Acid
60%
Clinical Assessment
20%
Enzyme Activity
20%
Adeno Associated Virus Vector
20%
Leukodystrophy
20%